Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has been given a consensus rating of “Buy” by the eight research firms that are currently covering the firm, Ratings reports. Seven research ...
(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...